Sware Raises $6M in Series B Funding to Advance Software Validation Solutions for Life Sciences


Sware, a Boston, MA-based company specializing in software validation solutions for life sciences, has secured $6 million in a Series B funding round. The investment will support further development of its Res_Q™ platform and expansion of its sales team.

Key Highlights:

  • Funding Amount: $6 million
  • Round: Series B
  • Location: Boston, MA
  • Lead Investor: First Analysis
  • Participating Investors: LRVHealth, New Stack Ventures, Insight Partners

Strategic Investors and Board Expansion:

  • New Board Member: Matt Nicklin, Managing Director at First Analysis, will join Sware’s board of directors as part of the investment.

Use of Funds:

  • Research and Development: Enhance the computer systems validation (CSV) platform, Res_Q, with advanced artificial intelligence (AI) capabilities.
  • Sales Team Expansion: Grow the sales team to support wider market reach and customer acquisition.

About Sware:

  • CEO: Ellen Reilly
  • Platform: Res_Q™
  • Functionality: Provides a comprehensive software validation solution that automates, integrates, and scales validation processes.
  • Target Industries: Pharmaceutical, medical device, and biotechnology companies.
  • Technology: Cloud-based platform with open API architecture, enabling control over all validation processes including IT, manufacturing, and lab systems.

Platform Benefits:

  • Eliminates Validation Debt: Streamlines validation processes, reducing backlog and inefficiencies.
  • Automation and Integration: Enhances operational efficiency by automating validation tasks.
  • Scalability: Scales with the growing needs of life sciences companies.
  • Centralized Control: Offers a unified system for managing all validation activities across various departments.


Sware’s Series B funding round will enable the company to further develop its Res_Q™ platform, integrating AI to streamline and enhance validation processes for life sciences companies. The investment also allows for the expansion of the sales team, positioning Sware for broader market penetration and accelerated growth. With the addition of Matt Nicklin to the board, Sware gains strategic insights and support from First Analysis, strengthening its capability to innovate and lead in the software validation space.

Related Stories